Results 51 to 60 of about 15,200 (191)

Lifelong evolution of autoreactive plasma cell numbers, affinity and anatomical location in arthritic K/BxN mice

Arthritis &Rheumatology, Accepted Article.
Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke, Carlos Castrillon, Odile Richard‐Le Goff, Angga Perima, Matteo Broketa, Andrew D. Griffiths, Patrick England, François Huetz, Pierre Bruhns   +8 more
wiley   +1 more source

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Haematologica, 2020
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja Weisel, Michele Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios A. Dimopoulos   +18 more
doaj   +1 more source

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

Journal for ImmunoTherapy of Cancer, 2021
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease.
Jennifer Yang, Anand D Jeyasekharan, Joanne Lee, Wee Joo Chng, Tae-Hoon Chung, Nurulhuda Mustafa, Adina Huey Fang Nee, Jing Yuan Chooi, Sabrina Hui Min Toh, Viknesvaran Selvarajan, Shuangyi Fan, Siok Bian Ng, Michelle Poon, Esther Chan, Yen Lin Chee, Longen Zhou   +15 more
doaj   +1 more source

Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The selective enrichment of cell populations based on surface markers is critical for the advancement of gene and cell therapies. Current antibody‐based cell isolation methods, such as fluorescence‐ and magnetic‐activated cell sorting (FACS and MACS), offer high specificity but are limited by scalability, cost, and potential adverse effects on
Gabrielle Rusch, Mickael Meyer, I. Mohamed Irfan, Carson Huber, Joseph Burclaff, Scott T. Magness, Stefano Menegatti, Michael Daniele   +7 more
wiley   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

Cells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner, Niels W. C. J. van de Donk, Paul G. Richardson   +2 more
doaj   +1 more source

Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

Frontiers in Immunology, 2023
BackgroundLate or chronic active antibody-mediated rejection (AMR) associated with de novo donor-specific antibodies (dnDSA) after renal transplantation is a great clinical challenge because it is often resistant to conventional therapies.
Lan Zhu, Lan Zhu, Lan Zhu, Lan Zhu, Zhiliang Guo, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Rula Sa, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Hui Guo, Hui Guo, Hui Guo, Hui Guo, Gang Chen, Gang Chen, Gang Chen, Gang Chen   +21 more
doaj   +1 more source

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland [PDF]

, 2015
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss
Bargetzi, M., Betticher, D.C., Duchosal, M.A., Heim, D., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., Pabst, T., Renner, C., Samaras, P., Taverna, C., Zander, T.   +13 more
core   +4 more sources

A Refractory Leg Skin Ulcer Associated With Multiple Myeloma Successfully Treated With Plasma Exchange, Lenalidomide, and Dexamethasone

JEADV Clinical Practice, EarlyView.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder that primarily presents with CRAB symptoms (calcium elevation, renal failure, anemia, and bone abnormalities). In rare cases, MM manifests with systemic complications like skin ulcers, which present management challenges. Here, we report a 78‐year‐old Japanese man with MM and refractory
Naoko Hattori, Yutaka Kuwatsuka, Tomoka Waseda, Daisuke Ehara, Koji Ando, Hiroyuki Murota   +5 more
wiley   +1 more source

Daratumumab-induced transient myopic shift

American Journal of Ophthalmology Case Reports, 2019
Purpose: To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab. Observations: A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first ...
Maria A. Mavrommatis, Hoon Jung, Ajai Chari, Bart Barlogie, James G. Chelnis   +4 more
doaj   +1 more source